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Introduction
Radiation therapy with sources emitting gamma and beta
radiation has shown the ability to inhibit restenosis after
percutaneous coronary interventions [1]. Human trials with
endovascular gamma radiation demonstrated decreased
restenosis in patients with prior restenosis undergoing
repeat coronary angioplasty followed by radiotherapy
[2,3]. Non-randomized pilot studies with endovascular
beta radiation after balloon angioplasty showed a low late
lumen loss and a low restenosis rate in patients with de
novo lesions [4] as well as with in-stent restenosis [5].
PREVENT (Proliferation REduction with Vascular ENergy
Trial) was the first randomized placebo-controlled trial of
intracoronary beta radiation for the prevention of coronary
restenosis [6].
Trial design and results
The primary objective of this study was to demonstrate the
safety and performance of an intracoronary beta-radiation
therapy system (Guidant Vascular Intervention, Houston,
Texas). Secondary objectives included the evaluation of the
effectiveness of intravascular beta radiotherapy after stent
implantation (for the first time) in comparison with balloon
angioplasty alone, and the relative effectiveness of three
radiotherapy doses (16, 20 and 24 Gy beyond the lumen
surface) in comparison with a sham radiation procedure
(placebo). Radiotherapy was applied to restenotic as well
as de novo lesions shorter than 15 mm, with a maximal total
treatment length (balloon or stent) of 22 mm or less and a
reference vessel diameter of between 2.4 and 3.7 mm inclu-
sive. The intravascular radiation therapy system, the dosime-
try and the procedure have been described previously in
detail [6,7]. The system consists of three components: the
27 mm  32P source wire, the centering spiral balloon
catheter, and the automated source delivery unit. All
patients received aspirin (325 mg) for the duration of the
study, and ticlopidine (250 mg bid) for 4 weeks afterwards
for patients who had received a procedural stent.
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Abstract
PREVENT was the first prospective, randomized placebo-controlled study of intracoronary beta
radiotherapy with 32P. A total of 105 patients with de novo or restenotic lesions, treated by stenting or
balloon angioplasty, received 0 (control), 16, 20, or 24 Gy to a depth of 1 mm beyond the lumen
surface. Rates of restenosis (50% diameter stenosis or more) were significantly lower in radiotherapy
patients at the target site (8% compared with 39%, P = 0.012) and at the target site plus adjacent
segments (22% compared with 50%, P = 0.018). Stenosis adjacent to the target site and late
thrombotic events reduced the overall clinical benefit of radiotherapy.
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A total of 105 patients had a successful procedure. Patients
were randomized to one of four radiation treatment groups:
0 (placebo, n = 25), 16 Gy (n = 26), 20 Gy (n = 27), or
24 Gy (n = 27) to 1 mm beyond the lumen surface. Only the
radiation oncologist, medical physicist, and the radiation
safety officer were not blinded to treatment assignment.
Clinical follow-up was obtained at 1, 3, and 6 months.
Angiographic follow-up was mandated after 6 months.
The randomization was unbalanced (3:1) to detect any
safety issues that would occur with radiation at a high fre-
quency. Binary incidence rates, angiographic restenosis,
target-related revascularization or failure, or combined
nonspecific late ischemic end points were tested with c2
or exact contingency table analyses. Continuous variables
were compared by using Student’s t test.
Overall, 73 (70%) were de novo lesions, whereas 32
(30%) were restenotic lesions, including in-stent restenosis
in 24% of patients. The angioplasty procedure included the
placement of one or more new stents in 64 (61%) patients.
In-hospital major adverse clinical event (MACE) occurred
in one (1.3%) radiotherapy patient [non-Q-wave myocar-
dial infarction (MI)] and one (4.0%) control patient (non-Q-
wave MI) (P = ns). There were no instances of in-hospital
death or post-procedure revascularization.
Long-term (12 months) MACE [death, MI and target lesion
revascularization (TLR)] occurred in 13 (16%) of the radio-
therapy patients and in 6 (24%) of the control patients
(P = ns). If revascularization due to restenosis at any site in
the target vessel is included, MACE occurred in 21 (26%)
of the radiotherapy patients and in 8 (32%) of the control
patients (P = ns).
The one death and all seven post-hospitalization MIs
occurred in the radiotherapy group and were considered
to be acute late occlusive events. Six of the seven patients
with post-hospitalization MIs had received new stents at
the index procedure. The incidence of composite and indi-
vidual MACEs is presented in Table 1.
TLR was significantly lower in the radiotherapy group than
in the control group. There was a trend toward a lower inci-
dence of revascularization for restenosis at any site in the
target vessel (TVR) in the radiotherapy patients. The results
of the quantitative coronary analysis (QCA) are summa-
rized in Table 2. The target site was defined as the
segment of balloon and stent injury required to treat the
target lesion. Adjacent segments were defined as the seg-
ments of artery outside the target site and extended to
5 mm beyond the radiation zone. QCA showed no signifi-
cant differences between radiotherapy patients who
received new stents and those who underwent balloon
angioplasty. In addition, all three dose groups demon-
strated similar decreases in angiographic restenosis
indices in comparison with the control group, although the
trial population was not large enough for statistically mean-
ingful comparisons between subgroups. In patients with
follow-up angiography who received 16 Gy (n = 23), 20 Gy
(n = 25), and 24 Gy (n = 25), similarly low late lumen
losses (0.12 ± 0.49, 0.31 ± 0.79, and 0.23 ± 0.48 mm,
respectively) and late loss indices (4 ± 28%, 18 ± 50%,
and 10 ± 25%, respectively) were found.
Table 1
Major adverse clinical events at 12 months
Radiotherapy Control 
Event (n = 80) (n = 25) P value
MACE (death, MI, TLR) 13 (16%) 6 (24%) ns
MACE (death, MI, TVR) 21 (26%) 8 (32%) ns
Death 1 (1%) 0 (0%) ns
MI
Total 8 (10%) 1 (4%) ns
Q-wave 2 (3%) 0 (0%)
non-Q-wave 6 (7%) 1 (4%)
TLR5 (6%) 6 (24%) <0.05
TVR 17 (21%) 8 (32%) ns
MACE, major adverse clinical events; MI, myocardial infarction; TLR,
target lesion revascularization; TVR, target vessel revascularization.
Table 2
Quantitative coronary angiographic analysis
32P group (n = 80) Control (n = 25) P value
Acute gain (mm) 1.9 ± 0.6 (n = 80) 1.9 ± 0.4 (n = 25) ns
Late lumen loss (mm) 0.2 ± 0.6 (n = 73) 1.1 ± 0.7 (n = 23) <0.0001
Late loss index (%) 11 ± 36 (n = 73) 55 ± 30 (n = 23) <0.0001
Binary restenosis (>50%)
Target site 6/73 (8%) 9/23 (39%) 0.0012
Target site plus adjacent segments 17/76 (22%) 12/24 (50%) 0.018
All values are means ± SD.Current Controlled Trials in Cardiovascular Medicine    Vol 2 No 1 Raizner and Kaluza
The efficacy of beta radiotherapy with 32P
PREVENT was the first trial of beta radiotherapy for the
prevention of restenosis to use a control group. Although
it was a pilot study designed to assess the safety of beta
radiotherapy with 32P, valuable information was obtained
about the efficacy of beta radiotherapy. In the target site
there was a marked decrease in late lumen loss and late
loss index. Additionally, angiographic restenosis was
decreased by 79%. If one incorporates adjacent seg-
ments into the restenosis calculation, an almost equally
impressive 55% decrease was achieved by radiotherapy
(Table 2). Radiotherapy with 32P therefore seems to be as
effective as gamma radiotherapy [2,3] in reducing resteno-
sis after angioplasty.
The study population consisted of the broad spectrum of
patients undergoing percutaneous coronary intervention,
including in-stent restenosis; newly placed stents were
included. In patients receiving stents, radiotherapy was
administered after stent placement and completion of the
angioplasty procedure. This is in contrast with the Beta
Energy Restenosis Trial (BERT) of beta radiotherapy with
90Sr/90Y, in which stenting was performed after radiother-
apy had been administered [4]. Because beta radiation is
less penetrating than gamma radiation and does not pene-
trate stainless steel stents, a concern existed that beta
radiotherapy would be ineffective when administered to
stented arteries. This trial proved the contrary, indicating
that beta radiotherapy with 32P inhibited restenosis in
stented arteries as effectively as in non-stented arteries.
Quantitative coronary angiography showed no significant
differences between patients who received stents
(n = 50) and those who received balloon angioplasty
(n = 30) in late lumen loss (0.20 ± 0.50 mm compared
with 0.25 ± 0.74 mm; P = ns) or in late loss index
(9 ± 28% compared with 13 ± 46%; P = ns). This obser-
vation allowed the initiation of the INtimal Hyperplasia Inhi-
bition with Beta In-stent Trial (INHIBIT), a multi-center
randomized control trial in patients with in-stent resteno-
sis. In addition, the similar efficacies of three dose levels
(16, 20 and 24 Gy to a 1 mm depth in the artery wall) sug-
gested that the therapeutic window for vascular radiother-
apy is not narrow.
The PREVENT trial was not designed or powered to show
efficacy based on clinical endpoints. Nevertheless, TLR
was significantly lower in the radiotherapy group (6% com-
pared with 24%, P < 0.05) and there was a distinct trend
observed in decreases in TVR (21% compared with 32%)
and MACE (death, MI, TLR) of 16% compared with 24%.
Side effects of radiation
Several potential radiation-related issues were identified in
this study. Despite the marked inhibition of the restenotic
process at the target site that received the full beam of
radiation, some patients developed narrowing at, or adja-
cent to, the edge of the radiation zone. Most cases of the
‘edge effect’ revealed evidence of balloon or stent injury
that was incompletely covered by the radiotherapy treat-
ment; a ‘geographic miss’. Consequently, the strategy of
incorporating a broad margin of treatment beyond the
segment of balloon or stent injury should lessen or elimi-
nate this phenomenon.
An additional observation of this investigation was the
occurrence of late MI in 7 radiotherapy patients during the
12-month follow-up. It is reasonable to speculate that the
cause of these late thrombotic events was the delayed for-
mation of ‘protective’ neointima over the exposed stent
material, thereby prolonging the potential for late stent
thrombosis to occur. On the basis of this observation, a
strategy of prolonged anti-platelet therapy (3–6 months)
and minimizing the use of new stents in patients undergo-
ing radiotherapy was advocated.
Operational characteristics of the Guidant
system
An important goal of this study was to assess the opera-
tional characteristics of the Guidant system. The system is
unique in that it incorporates a radiation delivery catheter
with a spiral balloon. The spiral balloon allows side-branch
and distal perfusion while centering the source. The
source is delivered by an after-loader (source delivery unit)
that allows hands-off operation of this radiotherapy unit,
and computer algorithms that precisely calculate dosi-
metry and dwell times. Dwell times range from 1.0 to
9.6 minutes (mean = 4.6) and the time added to the angio-
plasty procedure was only 12 ± 6 minutes. Fractionation
of the treatment was required in only 9% of patients.
Conclusions
In summary, PREVENT demonstrated that beta-radiother-
apy with 32P with an automated system and source center-
ing was a safe and potent inhibitor of restenosis in a broad
spectrum of patients undergoing percutaneous coronary
intervention. Several problems were identified, including an
‘edge effect’ due to a ‘geographic miss’, and late thrombo-
sis primarily in patients with newly implanted stents. The
trial supports the further exploration of beta radiotherapy in
larger-scale clinical trials of specific subsets of patients,
including those with in-stent restenosis.
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